NurExone Biologic Inc.

NurExone Biologic Inc. develops exosome-based nanodrugs aimed at treating central nervous system injuries. Its lead therapeutic candidate, ExoPTEN, combines exosomes with PTEN-inhibiting siRNA and is being advanced for acute spinal cord injury, with additional applications being explored for optic nerve and facial nerve injuries. The company utilizes its proprietary ExoTherapy platform to produce MSC-derived exosomes and load them with therapeutic cargo, targeting regenerative applications across various medical indications.